Qiagen (NYSE:QGEN) issued an update on its third quarter earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of ~$0.58 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $481.3 million, compared to the consensus revenue estimate of $462.67 million.Qiagen also updated its Q3 2020
Pre-Market guidance to 0.58-0.58 EPS.
Shares of NYSE:QGEN opened at $54.46 on Tuesday. The business’s 50 day moving average price is $51.02 and its 200-day moving average price is $45.78. Qiagen has a 1 year low of $27.00 and a 1 year high of $55.27. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 1,815.33, a price-to-earnings-growth ratio of 1.07 and a beta of 0.32. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.71 and a quick ratio of 1.50.
Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.55 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.55. Qiagen had a net margin of 0.86% and a return on equity of 15.85%. The business had revenue of $443.30 million for the quarter, compared to the consensus estimate of $441.80 million. During the same period last year, the firm posted $0.34 earnings per share. The company’s revenue was up 16.2% compared to the same quarter last year. On average, sell-side analysts expect that Qiagen will post 2.08 earnings per share for the current year.
Several brokerages recently commented on QGEN. Deutsche Bank Aktiengesellschaft upgraded Qiagen from a hold rating to a buy rating and boosted their price target for the stock from $32.00 to $60.00 in a research report on Friday, August 14th. Warburg Research reaffirmed a neutral rating on shares of Qiagen in a research note on Tuesday, June 23rd. Exane BNP Paribas upgraded shares of Qiagen from a neutral rating to an outperform rating in a report on Friday, August 14th. Bank of America upgraded Qiagen from a neutral rating to a buy rating and set a $59.00 target price on the stock in a report on Tuesday, October 6th. Finally, BNP Paribas raised Qiagen from a neutral rating to an outperform rating in a report on Friday, August 14th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $50.72.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
See Also: 52-Week High/Low
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.